A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-16. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
For example, RasGTP signals link with the mitogen activated protein kinase (MAPK) cascade to amplify the allosteric activation of proliferative transcription factors such as Myc and CREB. Earl Wilbur Sutherland Jr., discovered second messengers, for which he won the 1971 Nobel Prize in Physiology or Medicine. Sutherland saw that epinephrine would stimulate the liver to convert glycogen to glucose (sugar) in liver cells, but epinephrine alone would not convert glycogen to glucose. He found that epinephrine had to trigger a second messenger, cyclic AMP, for the liver to convert glycogen to glucose. The mechanisms were worked out in detail by Martin Rodbell and Alfred G. Gilman, who won the 1994 Nobel Prize. Secondary messenger systems can be synthesized and activated by enzymes, for example, the cyclases that synthesize cyclic nucleotides, or by opening of ion channels to allow influx of metal ions, for example Ca2+ signaling. These small molecules bind and activate protein kinases, ion channels, and other proteins, thus continuing the signaling cascade.
In Kwannon's first appearance, using the codename Revanche, she traveled to the United States to confront Braddock, believing herself to be the real Betsy Braddock due to amnesia caused by the body swap. She discovered that she was formerly the Hand's prime assassin before incurring brain damage and falling comatose as a result of a battle with her lover Matsu'o Tsurayaba, a high-ranking member of the Hand. In hopes that, due to Kwannon's low-level psychic abilities, the powers of the high-level telepath Betsy Braddock would be able to save her life, Tsurayaba sought the help of the sorceress Spiral, who instead transferred the women's minds into each other's bodies rather than simply recovering Kwannon. After accepting that she is not the original Betsy Braddock, Kwannon becomes a member of the X-Men, shortly thereafter contracting the Legacy Virus. As the disease progressed, Kwannon's psychic abilities increased, allowing her to clarify her own distorted memory. Choosing to die on her own terms, Kwannon confronts Tsurayaba, who complies with her request to kill her rather than waiting to succumb to the disease. Following the Hunt for Wolverine, when Braddock was restored to her original body, Kwannon was reborn in her original body as well. Claiming the codename Psylocke for herself, Kwannon became a citizen of the mutant nation of Krakoa. After the apparent murder of her long-lost daughter by a threatening artificial intelligence called Apoth, Psylocke assembled a new team of Fallen Angels with X-23 and Cable.
== Signs and symptoms == Nitrogen dioxide poisoning is harmful to all forms of life just like chlorine gas poisoning and carbon monoxide poisoning. It is easily absorbed through the lungs and its inhalation can result in heart failure and sometimes death in severe cases. Individuals and ethnicities may differ in nitrogen dioxide tolerance level and individual tolerance level for the gas may be altered by several factors, such as metabolic rate, barometric pressure, and hematological disorders but significant exposure may result in fatal conditions that could lead to shorter lifespan due to heart failure.
== Active site and mechanism of catalysis == The active site of eqolosin contains a distinctive glutamic acid and glutamine catalytic dyad which are involved in substrate binding and catalysis. These residues act as a nucleophile, with the glutamic acid serving as a general acid in the first phase of the reaction, donating a proton to the carbonyl oxygen in the peptide bond of the substrate. One or two water molecules may be involved in the reaction supplying a hydroxyl group, and the glutamic acid further donates a proton to the amide nitrogen, resulting in breakage of the peptide bond. The glutamine then returns the glutamic acid to its initial state.
a DNA template that contains the DNA target region to amplify a DNA polymerase; an enzyme that polymerizes new DNA strands; heat-resistant Taq polymerase is especially common, as it is more likely to remain intact during the high-temperature DNA denaturation process. Pfu polymerase is a heat-resistant polymerase with higher accuracy compared to Taq due to its ability to proofread, but it runs slower. Adding a small amount of Pfu to Taq combines the benefits of both.
Sources: en.wikipedia.org
== Stability == Fragile States Index 2015: Thailand ranked 71 of 178 nations (1=worst, 178=best). Lowest ranking ASEAN neighbour state is Myanmar, ranked 27, and Singapore, highest ranking, ranked 159.
Granzyme B also cleaves many of the proteins responsible for apoptosis in the absence of caspase activity. The other granzymes activate cell death by caspase-dependent and caspase-independent mechanisms. In addition to killing their target cells, granzymes can target and kill intracellular pathogens. Granzymes A and B induce lethal oxidative damage in bacteria by cleaving components of the electron transport chain, while granzyme B cleaves viral proteins to inhibit viral activation and replication. The granzymes bind directly to the nucleic acids DNA and RNA; this enhances their cleavage of nucleic acid binding proteins. More recently, in addition to T lymphocytes, granzymes have been shown to be expressed in other types of immune cells such as dendritic cells, B cells and mast cells. In addition, granzymes may also be expressed in non-immune cells such as keratinocytes, pneumocytes and chondrocytes. As many of these cell types either do not express perforin or do not form immunological synapses, granzyme B is released extracellularly. Extracellular granzyme B can accumulate in the extracellular space in diseases associated with dysregulated or chronic inflammation leading to the degradation of extracellular matrix proteins and impaired tissue healing and remodelling. Extracellular granzyme B has been implicated in the pathogenesis of atherosclerosis, aneurysm, vascular leakage, chronic wound healing, and skin aging.
=== Prader–Willi syndrome === Carbetocin was under development in an intranasal formulation for the treatment of Prader–Willi syndrome (PWS). It was variously developed by Ferring Pharmaceuticals, Levo Therapeutics, and Acadia Pharmaceuticals and had developmental code names including ACP-101, FE-992097, and LV-101. The drug reached and completed multiple phase 3 clinical trials for PWS prior to the discontinuation of its development in October 2025. It was discontinued due to lack of effectiveness.
Hogan – the hogan is the traditional dwelling of the Navajo people, constructed from timber, packed earth, and stone. Hogans come in two primary forms: the conical "male" forked-stick hogan used for ceremonies, and the larger circular or polygonal "female" hogan used as a family dwelling. The east-facing entrance aligns with Navajo cosmology, and new hogans are traditionally consecrated with a Blessingway ceremony. Hominy – this is a specialized corn dish known by many North American native people. Today, it is most commonly seen in the Southern United States. Hydraulic pressure – The Maya at Palenque (in modern-day Chiapas, Mexico) engineered the first known pressurized water system in the Americas. By constructing a subterranean aqueduct (the Piedras Bolas aqueduct) that narrowed significantly at the downstream end, they utilized hydraulic principles to create water pressure capable of shooting water upwards to a height of 6 meters (20 ft). This system was likely used for fountains or sanitary purposes, operating without the need for mechanical pumps.
Sources: en.wikipedia.org
(WINNER) The contestant won the whole competition. ‡ The contestant won the Pre-Heat challenge. (WIN) The contestant won the Main Heat challenge. (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant was eliminated for worst dish. (WDR) The contestant voluntarily left the competition.
A freeze alarm (also called a low-temperature alarm or freeze monitor) is a device that tracks ambient temperature and issues an alert when the temperature falls below a user-defined threshold. Its chief purpose is to warn property owners early enough to prevent freeze-related damage such as burst water pipes, failed heating systems, or losses to temperature-sensitive goods. Repairing a single burst pipe in a residence can cost well over US$10,000 on average, making proactive warnings financially attractive.
It appears that this gene loss has happened several times independently in evolutionary separated groups of animals. Lack of ghrelin and MBOAT4 may be relevant to the way that these reptiles can live at a low energy demand for months or years. Their fat stores are used at a low level. The presence of many mutations in genes for aspects of mitochondrial function in these animals may also be involved in their reduced energy demand.
Infliximab works by binding to TNF, stopping its inflammatory effects. It was initially used for the treatment of Crohn's disease and it became the first FDA approved TNF inhibitor in 1998. Infliximab as well as other TNF inhibitors like adalimumab, certolizumab, and golimumab are currently the most common biologics used in the treatment of both Crohn's disease and ulcerative colitis. The other main categories of biologics that treat IBD are integrin receptor antagonists such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab.
Investigation of possible scenarios of the origin of life: By testing different analogs, researchers try to answer the question of whether life's use of DNA and RNA was selected over time due to its advantages, or if they were chosen by arbitrary chance; As a tool to detect particular sequences: XNA can be used to tag and identify a wide range of DNA and RNA components with high specificity and accuracy; As an enzyme acting on DNA, RNA and XNA substrates - XNA has been shown to have the ability to cleave and ligate DNA, RNA and other XNA molecules similar to the actions of RNA ribozymes; As a tool with resistance to RNA hydrolysis; Investigation of the mechanisms used by enzyme; and Investigation of the structural features of nucleic acids.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.